Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Nordic Nanovector ASA ( (DE:8NN) ) has shared an announcement.
Thor Medical ASA announced the completion of a private placement, raising NOK 75 million in gross proceeds, and a separate retail offering in the Nordic countries, aiming to raise up to EUR 1 million. The company is also considering a subsequent share offering to existing shareholders, subject to market conditions and regulatory approvals. This strategic move is expected to bolster Thor Medical’s financial position and support its growth in the radiopharmaceutical industry.
More about Nordic Nanovector ASA
Thor Medical ASA is an emerging supplier in the radiopharmaceutical industry, specializing in the production of radionuclides, particularly alpha particle emitters derived from naturally occurring thorium. The company utilizes a proprietary production process that does not require irradiation or nuclear reactors, ensuring a reliable, environmentally friendly, and cost-efficient supply of alpha-emitters. Thor Medical is based in Oslo, Norway, and is listed on the Oslo Stock Exchange under the ticker symbol ‘TRMED’.
Average Trading Volume: 1,459,918
Current Market Cap: NOK929.1M
For detailed information about 8NN stock, go to TipRanks’ Stock Analysis page.